CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 4 enrolled
Drug / intervention
uridine triacetatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02110147
NCT02110147Phase 3Completed

Open-Label Study of Uridine Triacetate in Pediatric Patients With Hereditary Orotic Aciduria

Wellstat Therapeutics·interventional·Posted Apr 10, 2014·Updated Jul 31, 2017

In Brief

A Phase 3 clinical trial evaluating uridine triacetate for Hereditary Orotic Aciduria. Completed, enrolled 4 participants across 2 sites.

Detailed Summary

This protocol has two parts - the Main Study which is 42 days in length and the Treatment Extension which allows the patients who complete the Main Study to continue receiving treatment with uridine triacetate. The purpose of this study is to replace oral administration of uridine with oral administration of uridine triacetate in patients with hereditary orotic aciduria who have received (or would reasonably be expected to receive) clinical benefit from treatment with exogenous uridine. It is also to document the continued clinical benefit of exogenous uridine when patients are switched from oral administration of uridine to oral administration of uridine triacetate.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 10, 2014
Enrollment StartApr 1, 2014
Primary CompletionDec 1, 2014
Study CompletionSep 8, 2016
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 12.2 years ago

Interventions

uridine triacetatedrug